Stock Mumak

Stock Profile

Bayer

Bayer is making operational progress with improving profitability. However, litigation and high debt continue to weigh on the outlook.

Stock Snapshot

Bayer Logo
Table HeaderTable Header
CompanyBayer AG
SectorPharmaceuticals, Chemicals & Biotechnology
ThemeSelf-medication, pharmaceuticals, and agriculture
Business ModelSeeds, crop protection products, and the research, development, and patenting of prescription & over-the-counter medicines
ISINDE000BAY0017
Market Capitalizationapprox. €35.6 billion
UMBRELLA StatusWatchlist

Mumak Score Card

Geopolitics

Industry

Fundamentals

Sentiment

Technical Analysis

Price Performance (12 Months)

Posts on Bayer

Bayer AG
Pharmaceuticals, Chemicals & Biotechnology

Valuation Analysis: Bayer AG

ISIN: DE000BAY0017

Bayer is making operational progress with improving profitability. However, litigation and high debt continue to weigh on the outlook.
More research

Latest Portfolio Updates

Weekly Update

Weekly Market Overview – June 8-14, 2026

AI and healthcare innovation are shaping the markets. The UMBRELLA Strategy increases its focus on quality companies and reduces cyclical
Next Update
Weekly Update

Weekly Market Overview – June 1-7, 2026

The UMBRELLA strategy has completed its portfolio restructuring, further strengthening its focus on Artificial Intelligence, cloud infrastructure, and data analysis.
Next Update
Weekly Update

Weekly Market Overview – May 25–31, 2026

The UMBRELLA Strategy is placing a stronger emphasis on AI, technology, healthcare, and defense. Tesla remains the largest single position.
Next Update
Weekly Update

Weekly Market Overview – May 18-24, 2026

Tech strength supports markets, but robust US data fuels renewed interest rate concerns and weighs on renewable energy. Learn everything
Next Update